patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_875419 | REC_0002001 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 14.5 | 67 | female | 0 | 19 | 5 | 1 | entrectinib 600 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:35:57.338009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_283064 | REC_0002002 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 6.6 | 68 | female | 1 | 51 | 4.7 | 2 | pembrolizumab 200 mg q3w | 15.3 | false | MSS | 2026-03-15T05:35:57.338236+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255533 | REC_0002003 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 10 | 60 | female | 0 | 9 | 5.3 | 6 | pembrolizumab 200 mg q3w | 8.1 | false | MSI-H | 2026-03-15T05:35:57.338519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142439 | REC_0002004 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 3.4 | 74 | female | 1 | 16 | 4.8 | 2 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.338759+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480207 | REC_0002005 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 8.5 | 74 | female | 2 | 15 | 6.3 | 3 | entrectinib 600 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:57.339011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103771 | REC_0002006 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 10.8 | 70 | female | 2 | 10 | 6.4 | 6 | osimertinib 80 mg daily | 7.2 | false | MSI-H | 2026-03-15T05:35:57.339257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686097 | REC_0002007 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 12.9 | 82 | female | 1 | 17 | 5.8 | 6 | alectinib 600 mg BID | 11.9 | true | MSS | 2026-03-15T05:35:57.339507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285110 | REC_0002008 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 10.9 | 69 | female | 1 | 17 | 7.1 | 4 | osimertinib 80 mg daily | 5.9 | false | MSI-H | 2026-03-15T05:35:57.339756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207042 | REC_0002009 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 9.4 | 65 | male | 0 | 22 | 6.7 | 5 | sotorasib 960 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:57.339994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709843 | REC_0002010 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.9 | 68 | female | 1 | 69 | 4.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.8 | true | MSS | 2026-03-15T05:35:57.340312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690590 | REC_0002011 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 31 | 13.6 | 75 | female | 2 | 14 | 6.5 | 0 | entrectinib 600 mg daily | 8.5 | false | MSI-H | 2026-03-15T05:35:57.340558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608353 | REC_0002012 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 9.3 | 66 | male | 0 | 14 | 4.9 | 1 | entrectinib 600 mg daily | 26.8 | true | MSS | 2026-03-15T05:35:57.340797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765419 | REC_0002013 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 16 | 5.1 | 68 | female | 1 | 20 | 4.6 | 2 | pembrolizumab 200 mg q3w | 12.1 | true | MSS | 2026-03-15T05:35:57.341028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885590 | REC_0002014 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 14.2 | 67 | female | 0 | 19 | 7.3 | 1 | osimertinib 80 mg daily | 20.4 | true | MSI-H | 2026-03-15T05:35:57.341266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936218 | REC_0002015 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 11.9 | 63 | male | 1 | 12 | 4.3 | 1 | entrectinib 600 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:35:57.341505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648054 | REC_0002016 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 4.6 | 79 | female | 2 | 8 | 6.8 | 6 | pembrolizumab 200 mg q3w | 5.2 | true | MSS | 2026-03-15T05:35:57.341835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271888 | REC_0002017 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 10.8 | 69 | female | 1 | 15 | 7 | 5 | pembrolizumab 200 mg q3w | 11.9 | true | MSS | 2026-03-15T05:35:57.342076+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747923 | REC_0002018 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 10.1 | 71 | female | 3 | 3 | 5.5 | 4 | sotorasib 960 mg daily | 10.1 | false | MSS | 2026-03-15T05:35:57.342306+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190599 | REC_0002019 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.2 | 70 | female | 2 | 65 | 3.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.2 | false | MSS | 2026-03-15T05:35:57.342541+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683818 | REC_0002020 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 13 | 14.3 | 61 | female | 1 | 8 | 6.2 | 5 | osimertinib 80 mg daily | 4.3 | false | MSI-H | 2026-03-15T05:35:57.342784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132702 | REC_0002021 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 16 | 5 | 78 | female | 1 | 19 | 3.9 | 1 | pembrolizumab 200 mg q3w | 9 | false | MSS | 2026-03-15T05:35:57.343011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912691 | REC_0002022 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 16.6 | 58 | female | 1 | 23 | 6.7 | 4 | alectinib 600 mg BID | 12.7 | true | MSS | 2026-03-15T05:35:57.343245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_783774 | REC_0002023 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 6.8 | 81 | female | 1 | 15 | 6.4 | 4 | sotorasib 960 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:57.343473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799276 | REC_0002024 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 13.5 | 78 | female | 2 | 19 | 6.2 | 1 | pembrolizumab 200 mg q3w | 22.7 | false | MSS | 2026-03-15T05:35:57.343707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421979 | REC_0002025 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 12.4 | 67 | female | 0 | 16 | 6.9 | 1 | alectinib 600 mg BID | 12.2 | true | MSS | 2026-03-15T05:35:57.343942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819706 | REC_0002026 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 11.5 | 68 | female | 1 | 26 | 6.3 | 1 | entrectinib 600 mg daily | 22.2 | true | MSI-H | 2026-03-15T05:35:57.344221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645385 | REC_0002027 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.5 | 72 | female | 1 | 30 | 6.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.7 | false | MSS | 2026-03-15T05:35:57.344456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285063 | REC_0002028 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 5.2 | 63 | female | 0 | 39 | 5.6 | 0 | carboplatin + paclitaxel + pembrolizumab | 21.6 | true | MSS | 2026-03-15T05:35:57.344692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740219 | REC_0002029 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 9.6 | 75 | female | 2 | 11 | 6.4 | 7 | pembrolizumab 200 mg q3w | 11.2 | false | MSS | 2026-03-15T05:35:57.344982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899017 | REC_0002030 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 11.3 | 65 | female | 0 | 17 | 7.3 | 7 | entrectinib 600 mg daily | 11.4 | false | MSS | 2026-03-15T05:35:57.345223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_851264 | REC_0002031 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 14.4 | 60 | male | 0 | 22 | 4.3 | 1 | alectinib 600 mg BID | 28.8 | true | MSS | 2026-03-15T05:35:57.345461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905327 | REC_0002032 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 4.9 | 59 | male | 1 | 24 | 7.1 | 5 | osimertinib 80 mg daily | 11.4 | false | MSS | 2026-03-15T05:35:57.345692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731766 | REC_0002033 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 7.6 | 70 | male | 2 | 16 | 5.5 | 6 | osimertinib 80 mg daily | 16.7 | true | MSS | 2026-03-15T05:35:57.345925+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907463 | REC_0002034 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 5.2 | 75 | male | 2 | 33 | 3.3 | 6 | pembrolizumab 200 mg q3w | 11 | true | MSS | 2026-03-15T05:35:57.346159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234765 | REC_0002035 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 33 | 11.3 | 90 | female | 1 | 13 | 6 | 7 | pembrolizumab 200 mg q3w | 12.6 | true | MSI-H | 2026-03-15T05:35:57.346393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673187 | REC_0002036 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 7 | 63 | female | 1 | 18 | 7.2 | 6 | pembrolizumab 200 mg q3w | 13.7 | false | MSS | 2026-03-15T05:35:57.346626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122887 | REC_0002037 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9 | 73 | female | 3 | 10 | 3.9 | 6 | osimertinib 80 mg daily | 7.9 | false | MSS | 2026-03-15T05:35:57.346863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734539 | REC_0002038 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 9.4 | 68 | female | 1 | 15 | 5.3 | 4 | pembrolizumab 200 mg q3w | 12.4 | true | MSS | 2026-03-15T05:35:57.347090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967678 | REC_0002039 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 10.9 | 70 | female | 2 | 9 | 6.1 | 6 | entrectinib 600 mg daily | 17.4 | false | MSI-H | 2026-03-15T05:35:57.347321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379512 | REC_0002040 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.6 | 71 | female | 2 | 8 | 4 | 5 | pembrolizumab 200 mg q3w | 15 | false | MSS | 2026-03-15T05:35:57.347548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351802 | REC_0002041 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 19 | 14.2 | 60 | male | 1 | 22 | 4.6 | 0 | entrectinib 600 mg daily | 38.4 | true | MSS | 2026-03-15T05:35:57.347781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704647 | REC_0002042 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 9.2 | 72 | female | 1 | 16 | 6.3 | 2 | alectinib 600 mg BID | 15.3 | true | MSS | 2026-03-15T05:35:57.348051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862196 | REC_0002043 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 9.1 | 73 | female | 2 | 17 | 3.5 | 1 | pembrolizumab 200 mg q3w | 23.4 | false | MSS | 2026-03-15T05:35:57.348330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856595 | REC_0002044 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 14.4 | 68 | male | 1 | 8 | 4.4 | 8 | sotorasib 960 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:35:57.348572+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473792 | REC_0002045 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 10.8 | 67 | female | 0 | 19 | 6.6 | 6 | alectinib 600 mg BID | 17.2 | false | MSI-H | 2026-03-15T05:35:57.348809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699289 | REC_0002046 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 10.9 | 56 | male | 1 | 15 | 5.1 | 2 | osimertinib 80 mg daily | 27.9 | true | MSS | 2026-03-15T05:35:57.349042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627427 | REC_0002047 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 34 | 8.1 | 77 | male | 1 | 11 | 5.7 | 4 | alectinib 600 mg BID | 7 | true | MSS | 2026-03-15T05:35:57.349276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363144 | REC_0002048 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 8.5 | 57 | male | 1 | 8 | 6.4 | 7 | sotorasib 960 mg daily | 4.6 | true | MSS | 2026-03-15T05:35:57.349505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224531 | REC_0002049 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14.1 | 52 | female | 0 | 27 | 5.9 | 4 | osimertinib 80 mg daily | 11.6 | true | MSI-H | 2026-03-15T05:35:57.349739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954693 | REC_0002050 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 8.4 | 74 | female | 2 | 14 | 6.5 | 5 | osimertinib 80 mg daily | 6.4 | false | MSS | 2026-03-15T05:35:57.349967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216808 | REC_0002051 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 13.9 | 65 | male | 0 | 12 | 6.6 | 3 | sotorasib 960 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:57.350201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_299683 | REC_0002052 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 7 | 74 | female | 2 | 12 | 4.2 | 1 | osimertinib 80 mg daily | 5 | true | MSS | 2026-03-15T05:35:57.350429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142956 | REC_0002053 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 8.8 | 64 | male | 0 | 27 | 6.9 | 1 | osimertinib 80 mg daily | 20.5 | false | MSS | 2026-03-15T05:35:57.350658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501058 | REC_0002054 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 8.2 | 72 | female | 1 | 18 | 5.8 | 7 | sotorasib 960 mg daily | 15.2 | true | MSS | 2026-03-15T05:35:57.350886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253143 | REC_0002055 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 17.2 | 66 | female | 1 | 18 | 2.4 | 5 | pembrolizumab 200 mg q3w | 7.5 | true | MSS | 2026-03-15T05:35:57.351166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295829 | REC_0002056 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 10.7 | 66 | female | 1 | 19 | 4.3 | 6 | alectinib 600 mg BID | 18.5 | false | MSI-H | 2026-03-15T05:35:57.351400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138322 | REC_0002057 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 3.4 | 73 | female | 3 | 17 | 6 | 3 | pembrolizumab 200 mg q3w | 9.5 | false | MSS | 2026-03-15T05:35:57.351628+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885069 | REC_0002058 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 17.5 | 70 | female | 1 | 8 | 5.8 | 2 | osimertinib 80 mg daily | 33.7 | false | MSS | 2026-03-15T05:35:57.351862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960163 | REC_0002059 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.7 | 64 | male | 0 | 19 | 5.8 | 7 | alectinib 600 mg BID | 9.1 | true | MSS | 2026-03-15T05:35:57.352142+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884411 | REC_0002060 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 14.9 | 72 | male | 2 | 21 | 4.2 | 6 | alectinib 600 mg BID | 15 | false | MSS | 2026-03-15T05:35:57.352388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459040 | REC_0002061 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 12.1 | 65 | female | 0 | 10 | 4.2 | 5 | sotorasib 960 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:57.352623+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502680 | REC_0002062 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 9.8 | 67 | female | 0 | 15 | 3.6 | 6 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:57.352851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996078 | REC_0002063 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 2.9 | 81 | female | 2 | 13 | 5.3 | 2 | pembrolizumab 200 mg q3w | 13.8 | false | MSS | 2026-03-15T05:35:57.353084+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360016 | REC_0002064 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 17.2 | 62 | female | 1 | 22 | 5.8 | 2 | alectinib 600 mg BID | 25.3 | false | MSS | 2026-03-15T05:35:57.353321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998762 | REC_0002065 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 15.8 | 65 | male | 0 | 21 | 6.1 | 2 | osimertinib 80 mg daily | 15.4 | false | MSI-H | 2026-03-15T05:35:57.353557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342027 | REC_0002066 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 9.2 | 73 | female | 1 | 68 | 4.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 8 | false | MSS | 2026-03-15T05:35:57.353818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116336 | REC_0002067 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 16.6 | 61 | female | 1 | 17 | 5.3 | 6 | pembrolizumab 200 mg q3w | 9 | false | MSI-H | 2026-03-15T05:35:57.354066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_682613 | REC_0002068 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 34 | 12.7 | 52 | male | 0 | 17 | 5 | 5 | alectinib 600 mg BID | 7.5 | true | MSI-H | 2026-03-15T05:35:57.354415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748544 | REC_0002069 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 12.4 | 45 | female | 0 | 18 | 4.8 | 8 | osimertinib 80 mg daily | 9 | false | MSS | 2026-03-15T05:35:57.354688+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845496 | REC_0002070 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 6.1 | 69 | female | 1 | 57 | 8.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 29.5 | true | MSS | 2026-03-15T05:35:57.354941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236101 | REC_0002071 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 27 | 6.9 | 65 | male | 0 | 33 | 6.2 | 0 | pembrolizumab 200 mg q3w | 44.5 | false | MSS | 2026-03-15T05:35:57.355200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_273602 | REC_0002072 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 18 | 1.5 | 66 | male | 0 | 8 | 5.8 | 2 | pembrolizumab 200 mg q3w | 24.5 | true | MSS | 2026-03-15T05:35:57.355458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401592 | REC_0002073 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 4.8 | 68 | female | 1 | 69 | 6.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.3 | true | MSS | 2026-03-15T05:35:57.355708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476630 | REC_0002074 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.9 | 62 | male | 1 | 16 | 5.7 | 5 | osimertinib 80 mg daily | 6.1 | false | MSI-H | 2026-03-15T05:35:57.355972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769181 | REC_0002075 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 6.8 | 69 | female | 0 | 30 | 4.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 4.4 | true | MSS | 2026-03-15T05:35:57.356366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445690 | REC_0002076 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 15.1 | 69 | female | 0 | 10 | 4.7 | 6 | alectinib 600 mg BID | 8.3 | false | MSS | 2026-03-15T05:35:57.356627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553083 | REC_0002077 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 10.9 | 55 | female | 1 | 25 | 6.8 | 2 | sotorasib 960 mg daily | 14.5 | true | MSI-H | 2026-03-15T05:35:57.356876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312671 | REC_0002078 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 8.3 | 73 | female | 2 | 18 | 6 | 3 | entrectinib 600 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:57.357113+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540502 | REC_0002079 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 1.8 | 79 | female | 2 | 40 | 4 | 1 | pembrolizumab 200 mg q3w | 22.5 | false | MSS | 2026-03-15T05:35:57.357349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539098 | REC_0002080 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 8.1 | 88 | female | 1 | 7 | 5.2 | 6 | osimertinib 80 mg daily | 13.7 | true | MSS | 2026-03-15T05:35:57.357583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378908 | REC_0002081 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 11.3 | 73 | female | 2 | 16 | 7.1 | 2 | entrectinib 600 mg daily | 20.1 | true | MSS | 2026-03-15T05:35:57.357947+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352471 | REC_0002082 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 11.9 | 62 | male | 0 | 21 | 4 | 1 | osimertinib 80 mg daily | 7.6 | true | MSS | 2026-03-15T05:35:57.358188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577768 | REC_0002083 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 13.4 | 64 | female | 0 | 30 | 7.5 | 5 | alectinib 600 mg BID | 9.7 | false | MSI-H | 2026-03-15T05:35:57.358423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823108 | REC_0002084 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 8.7 | 66 | female | 1 | 49 | 4.2 | 5 | pembrolizumab 200 mg q3w | 10.9 | true | MSS | 2026-03-15T05:35:57.358656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237903 | REC_0002085 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13.1 | 55 | male | 1 | 9 | 4.3 | 5 | osimertinib 80 mg daily | 8.3 | true | MSI-H | 2026-03-15T05:35:57.358912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169689 | REC_0002086 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 13 | 64 | female | 0 | 15 | 5 | 1 | alectinib 600 mg BID | 23.5 | false | MSI-H | 2026-03-15T05:35:57.359167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787899 | REC_0002087 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 14.4 | 66 | female | 1 | 16 | 4.4 | 2 | entrectinib 600 mg daily | 27.1 | false | MSI-H | 2026-03-15T05:35:57.359414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373030 | REC_0002088 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 13 | 47 | male | 0 | 13 | 5.1 | 3 | sotorasib 960 mg daily | 7 | false | MSS | 2026-03-15T05:35:57.359663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560504 | REC_0002089 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 11.2 | 90 | female | 2 | 4 | 2.9 | 1 | sotorasib 960 mg daily | 26.6 | false | MSI-H | 2026-03-15T05:35:57.359900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932421 | REC_0002090 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 15 | 77 | female | 2 | 19 | 6.3 | 2 | alectinib 600 mg BID | 24 | true | MSS | 2026-03-15T05:35:57.360198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940569 | REC_0002091 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 7.4 | 71 | male | 2 | 17 | 3.6 | 1 | osimertinib 80 mg daily | 16 | false | MSS | 2026-03-15T05:35:57.360443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577767 | REC_0002092 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.3 | 71 | female | 2 | 8 | 7 | 6 | pembrolizumab 200 mg q3w | 10.6 | false | MSS | 2026-03-15T05:35:57.360676+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616147 | REC_0002093 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 11.7 | 56 | male | 1 | 12 | 5.3 | 3 | alectinib 600 mg BID | 4 | false | MSI-H | 2026-03-15T05:35:57.360917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182163 | REC_0002094 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 11.6 | 64 | male | 0 | 13 | 6.1 | 5 | alectinib 600 mg BID | 12.7 | false | MSS | 2026-03-15T05:35:57.361270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922962 | REC_0002095 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 15.2 | 67 | female | 0 | 11 | 6.2 | 2 | entrectinib 600 mg daily | 18.9 | true | MSS | 2026-03-15T05:35:57.361514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288697 | REC_0002096 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12 | 52 | female | 0 | 12 | 5.3 | 6 | alectinib 600 mg BID | 15 | false | MSI-H | 2026-03-15T05:35:57.361752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_917101 | REC_0002097 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 17.7 | 79 | female | 1 | 12 | 7.2 | 2 | osimertinib 80 mg daily | 15.4 | true | MSS | 2026-03-15T05:35:57.361984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748084 | REC_0002098 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 6.8 | 78 | female | 1 | 26 | 4.6 | 4 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.362214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960710 | REC_0002099 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 31 | 5.7 | 60 | female | 0 | 15 | 4.6 | 0 | entrectinib 600 mg daily | 28.8 | false | MSS | 2026-03-15T05:35:57.362448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621154 | REC_0002100 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 9.8 | 61 | female | 0 | 17 | 4.1 | 0 | sotorasib 960 mg daily | 16.5 | true | MSS | 2026-03-15T05:35:57.362679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.